irradiation therapy

RADIATION2 trials

Sponsors

Masonic Cancer Center, University of Minnesota, Noxopharm Limited

Conditions

CancerLymphoma

Phase 1

Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer

CompletedNCT03307629

Noxopharm LimitedCancer

Start: 2017-11-01End: 2020-09-15Updated: 2025-07-29

Phase 2

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

CompletedNCT00345865

Masonic Cancer Center, University of MinnesotaLymphoma

Start: 2005-08-24End: 2019-06-28Updated: 2020-07-14

Related Papers

Phase I study of a novel S1P inhibitor, NOX66, in combination with radiotherapy in patients with metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology2020-05-204 citations